Current Hematologic Malignancy Reports

Should Patients with Low-Risk Myelodysplastic Syndrome be Treated Earlier in the Course of Their Disease?

• CLINICAL TRIAL REPORT

Eric J. Feldman

Survival Advantage in CLL with Frontline FCR Therapy

• CLINICAL TRIAL REPORT

Susan O’Brien

Therapeutic Modalities for Patients with Lower-Risk Myelodysplastic Syndromes: Current Options and Future Directions

Shyamala C. Navada, Lewis R. Silverman

The Search for Better Prognostic Models in Myelodysplastic Syndromes

Fabio P. S. Santos, Hagop Kantarjian, Guillermo Garcia-Manero, Farhad Ravandi

Future Therapies for the Myeloproliferative Neoplasms

Robyn Scherber, Ruben A. Mesa

Special Issues in Myeloproliferative Neoplasms

Tiziano Barbui, Guido Finazzi

What is the Best Frontline Therapy for Patients with CLL and 17p Deletion?

Xavier C. Badoux, Michael J. Keating, William G. Wierda

The Role of Transplantation in Diffuse Large B-Cell Lymphoma: The Impact of Rituximab Plus Chemotherapy in First-line and Relapsed Settings

Celso Arrais Rodrigues, Poliana Alves Patah, Yana A. S. Novis, Chitra Hosing, Marcos de Lima

Burkitt Lymphoma and Atypical Burkitt or Burkitt-like Lymphoma: Should These be Treated as Different Diseases?

Deborah A. Thomas, Susan O’Brien, Stefan Faderl, John T. Manning Jr, Jorge Romaguera, Luis Fayad, Fredrick Hagemeister, Jeffrey Medeiros, Jorge Cortes, Hagop Kantarjian

The Emerging Role of Histone Deacetylase Inhibitors in Treating T-cell Lymphomas

Steven M. Horwitz